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Review

Can weight loss prevent cancer?
KY Wolin*,1 and GA Colditz1
1

Department of Surgery and Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA

We review and update evidence on obesity, weight gain and weight loss in relation to leading cancers since the International Agency
for Research on Cancer report of 2002. Emphasis is placed on the time course of disease and implications for weight control to
prevent cancer. We conclude that weight loss could prevent a major portion of common cancers.
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In 2002, the International Agency for Research on Cancer (IARC)
reviewed the evidence for an association between body weight and
cancer (International Agency for Research on Cancer, 2002). The
IARC concluded that sufficient evidence existed for avoiding
weight gain to protect against cancer. This evidence applied to
colon, breast (postmenopausal), endometrial, kidney (renal cell)
and oesophageal cancers. No effect was found for premenopausal
breast cancer, and insufficient evidence was available for all other
cancers. The IARC further found insufficient evidence for a
protective benefit of intentional weight loss for any cancer site.
The cancers for which insufficient evidence was found include
ovarian, prostate, lung, pancreatic, head and neck, testicular,
thyroid, gall bladder, melanoma and cervical cancer. The
IARC committee did not consider evidence for non-Hodgkin’s
lymphoma, myeloma or meningioma as very few studies could be
found to adequately evaluate risk.
In 2007, the World Cancer Research Fund and American
Institute for Cancer Research (WCRF/AICR) issued summary
findings on the association of obesity with cancer (World Cancer
Research Fund/American Institute for Cancer Research, 2007).
Convincing evidence was found for body fatness and colorectal,
pancreatic, oesophageal, postmenopausal breast, kidney and
endometrial cancers as well as for the association of abdominal
fatness and colorectal cancer. Probable evidence existed for
body fatness and gall bladder and premenopausal breast cancers
and for abdominal fatness and endometrial, pancreatic and
postmenopausal breast cancers. Suggestive evidence was found
for body fatness and lung and liver cancers. Despite the increasing
wealth of data on obesity and cancer, WCRF/AICR found sufficient
evidence to review the association with weight gain only for
postmenopausal breast cancer, concluding that a ‘probable’
association existed.
Thus, despite the extensive evidence showing a deleterious effect
of overweight and obesity on cancers (except for premenopausal
breast cancer where obesity appears protective), relatively little
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data exist on the effects of weight gain or weight loss on the risk of
cancer. The lack of data on weight loss is most likely a function
of the small number of individuals able to achieve sustained
weight loss.

METHODS
We review the evidence presented in the IARC and WCRF/AICR
reports and studies published subsequently for several major
cancers. A comprehensive review of studies published and indexed
on PubMed since the two reports was carried out. Selected studies
that highlight key findings are presented.

RESULTS
Colon cancer
Colon cancer is the second leading cause of cancer-related deaths
in the United States and the United Kingdom (http://info.
cancerresearchuk.org/cancerstats/mortality/cancerdeaths/) and the
fourth leading cause of cancer-related deaths worldwide (World
Health Organization, 2008). The risk of developing colon cancer is
thought to be reduced through a number of lifestyle factors, with
maintaining a healthy weight and physical activity being among
the most important. The IARC report found consistent positive
associations between body fatness, as indicated by body mass
index (BMI), and risk of colorectal cancer. Risk of colon cancer
was increased by 50 – 100% when comparing the highest and lowest
categories of BMI with a linear trend across levels of BMI. WCRF/
AICR concurred in 2007, finding convincing evidence that body
fatness increased the risk of colorectal cancer. Two subsequent
meta-analyses also found a significantly increased risk of colon
cancer with increasing BMI (Dai et al, 2007; Larsson and Wolk,
2007). Evidence for rectal cancer is less certain, with some studies
finding weak positive associations (Dai et al, 2007; Larsson and
Wolk, 2007) and others finding little evidence for an association
(International Agency for Research on Cancer, 2002).
Overweight and obesity appear to be more strongly related to
colon cancer incidence in men than in women (International
Agency for Research on Cancer, 2002; Dai et al, 2007; Larsson and
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Wolk, 2007). There is some evidence that hormones may modify
the association of obesity with colon cancer in women, as
oestrogen may increase susceptibility to the carcinogenic effects
of higher insulin levels associated with obesity (Giovannucci,
2002). The IARC report also found consistently increased risk of
colorectal adenomas when comparing the highest to lowest BMI
strata, which was supported in subsequent research (Kim et al,
2007). Gender differences are smaller for colorectal adenoma than
for colorectal cancer.
In addition to BMI, evidence exists that central body fat
distribution and abdominal fatness are associated with increased
risk of colon cancer and adenoma (International Agency for
Research on Cancer, 2002; Engeland et al, 2005; World Cancer
Research Fund/American Institute for Cancer Research, 2007).
Gender differences were also found for abdominal fatness (Larsson
and Wolk, 2007). Recent meta-analyses have provided further
support for the association (Dai et al, 2007; Larsson and Wolk,
2007).
Limited evidence is available on the association between weight
change and the risk of colon cancer. Studies suggest that adult
weight gain increases the risk of colorectal adenoma, the precursor
to most colorectal cancers (Bird et al, 1998; Kono et al, 1999).
For example, in a study of Japanese men undergoing colonoscopy,
Kono et al (1999) found that current, but not past, BMI was
positively associated with adenoma risk and that weight gain
over the past 10 years was positively associated with risk.
Researchers extracted weight for the previous 10 years from
medical records where it was recorded during the men’s
biannual health exam. Men who gained 6 kg or more were twice
as likely to have an adenoma as men who lost 2 kg or more. The
associations in these studies were strongest for larger adenomas.
Furthermore, Kono et al found that weight gain combined with a
high waist to hip ratio significantly increased risk, suggesting
that the distribution of weight gain may be as important as the
gain itself.
The IARC found limited evidence for an association between
weight change and the risk of colorectal cancer (International
Agency for Research on Cancer, 2002). Cohort studies examined
weight change from early adulthood to later in life and found
modest increases in risk (RRs between 1.4 and 1.6). Case – control
studies provided additional support. More recent evidence
indicates that weight gain in adulthood appears to increase the
risk of colon cancer. In a case – control study in Canada, men who
gained 21 kg or more since the age of 20 years were at 60%
increased risk of colorectal cancer as compared to men who had
gained 1 – 5 kg (Campbell et al, 2007). The association was stronger
when rectal tumours were excluded, suggesting that studies that
examine the association of weight gain on colorectal cancer may
underestimate the association for colon cancer. No association
between weight gain and colorectal cancer risk was observed
among women. Another study of men and women found that
compared to those who had remained BMI stable, those who
increased their BMI from the age of 30 or 50 years to diagnosis
were at 25 – 35% lower risk of colorectal cancer (Russo et al, 1998).
Finally, a study of Austrian adults found evidence for an inverse
association between weight loss and colon cancer in men (Rapp
et al, 2008).
Thus, weight appears to influence colon cancer risk at multiple
stages of carcinogenesis including initiation, promotion and
progression. Given the association with attained weight as a
dominant risk factor, avoiding weight gain could help avoid risk.
Because of the link between obesity and both large adenomas and
colon cancer, obesity may be acting at a later stage of tumour
development. Several mechanisms have been proposed to explain
the link between obesity and colon cancer (Bray, 2002;
Giovannucci, 2002). Weight loss and increased activity reduce
the circulating levels of insulin, a growth factor for colonic epithelial cells, and improve insulin sensitivity. Weight loss may also
British Journal of Cancer (2008) 99(7), 995 – 999

affect IGF and IGFBP levels. Insulin and IGF stimulate proliferation, inhibit apoptosis and have effects on cellular differentiation
and angiogenesis. Weight gain may also act by increasing levels of
prostaglandins, which decrease intestinal motility and increase cell
proliferation. Additional research on the timing of weight loss and
how it affects these potential mechanisms is merited.

Breast cancer
Breast cancer is a major cause of morbidity and the leading cause
of cancer mortality among women globally accounting for over
500 000 deaths per year (World Health Organization, 2008). The
IARC report concluded that obesity and weight gain are directly
and positively related to postmenopausal breast cancer (International Agency for Research on Cancer, 2002). The WCRF/AICR
concurred, finding convincing evidence for body fatness and
probable evidence for abdominal fat and weight gain (World
Cancer Research Fund/American Institute for Cancer Research,
2007). A meta-analysis conducted as part of the WCRF/AICR
report found a 5% increase in risk of postmenopausal breast
cancer with each 5 kg of weight gain.
Because sustained weight loss is not common, epidemiologic
data have been sparse on the benefits of weight loss in relation to
reduced risk of breast cancer. Weight gain was associated with
increased risk of postmenopausal breast cancer in several cohort
studies, particularly among women not taking supplemental
hormones (Eliassen et al, 2006; Han et al, 2006; Ahn et al, 2007).
In the prospective Nurses’ Health Study, weight gain after
menopause was directly related to risk of breast cancer (Eliassen
et al, 2006). As compared to women with stable weight, weight loss
significantly reduces risk. On the basis of these data, it is estimated
that adult weight gain accounts for 24% of postmenopausal breast
cancer and that weight gain after menopause accounts for 7% of
breast cancer among women who do not use postmenopausal
hormone therapy. However, these findings may not translate to all
groups, as no association was found among African-American
women, (Palmer et al, 2007), though the reasons for this remain
unclear.
Recent studies have elucidated mechanisms underlying weight,
weight loss and reduced risk of postmenopausal breast cancer.
Endogenous hormones are related not only to adiposity in
postmenopausal women but also to a oestrogen receptor-positive
breast cancer (Missmer et al, 2004). A year-long randomised trial
of activity among postmenopausal women shows that among
women who lost body fat, serum oestrogen levels were decreased
(McTiernan et al, 2004).
In contrast to the findings for postmenopausal breast cancer,
IARC found limited but supportive data for an inverse association
between both BMI and weight gain with premenopausal breast
cancer. WCRF/AICR concluded that there was a probable relation
between body fatness and premenopausal breast cancer, but it did
not examine weight gain or abdominal fatness. The IARC found no
support for a relation between premenopausal breast cancer and
central adiposity.

Prostate cancer
Prostate cancer is the sixth leading cause of cancer death among
men worldwide (World Health Organization, 2008), the second
leading cause of cancer death among US and British (http://
info.cancerresearchuk.org/cancerstats/mortality/cancerdeaths/) men
and the most common type of cancer found in men in the United
States and the United Kingdom (http://info.cancerresearchuk.org/
cancerstats/incidence/males/). Although 1 in 6 US men will get
prostate cancer in his lifetime, only 1 in 35 will die from the
disease. Links between prostate cancer and lifestyle factors are less
clear than those for breast and colon cancer.
& 2008 Cancer Research UK
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In its 2002 review, IARC found insufficient evidence to draw a
conclusion about the relationship between obesity and the risk of
prostate cancer (International Agency for Research on Cancer,
2002). However, there was a suggestion what whereas obesity was
not associated with the risk of prostate cancer overall, it might be
associated with fatal or aggressive disease. There were also
inconsistent associations between weight in young adulthood
and risk of prostate cancer. A subsequent meta-analysis found a
weak but statistically significant positive association between BMI
and prostate cancer risk, with stronger associations for more
advanced disease (MacInnis and English, 2006). In the 2007
WCRF/AICR report, insufficient evidence was found for body and
abdominal fatness (World Cancer Research Fund/American
Institute for Cancer Research, 2007).
Recent evidence suggests that obesity increases the risk for
advanced prostate cancer and prostate cancer mortality, but not
the risk of less aggressive disease. Several studies provide
significant support for the hypothesis that obesity increases the
risk of aggressive prostate cancer (Freedland and Platz, 2007;
Rodriguez et al, 2007; Wright et al, 2007).
Only a handful of studies have specifically examined the effects
of weight gain or loss on the risk of prostate cancer. For example,
in the Cancer Prevention Study II Nutrition Cohort, Rodriguez
et al observed a significantly decreased risk of high-grade prostate
cancer in men who lost 411 lbs as compared to those who were
weight-stable (change of p5 lbs) (Rodriguez et al, 2007). Similarly,
Cerhan observed a significant trend of reduced risk with weight
loss from the age of 50 years and increased risk with weight gain
from the age of 50 years relative to no change (Cerhan et al, 1997).
The association for BMI change from the age of 50 years was
stronger among men with BMI 424.4 kg m 2 at the age of 50 years.
Men who gained 410% weight and had a BMI 424.4 kg m 2 were
twice as likely to develop prostate cancer as men with BMI
p24.4 kg m 2 who, at baseline, were within 5% of their BMI at age
50. Finally, Wright et al found that weight gain from the age of 18
years significantly increased the risk of fatal, but not incident,
prostate cancer (Wright et al, 2007). However, not all studies have
found an association (Schuurman et al, 2000; Song et al, 2008).
A number of potential mechanisms have been hypothesised to
explain the observed associations and variations in study findings
(Freedland and Platz, 2007). Obesity may influence prostate cancer
detection. Obese men may have lower PSA levels, though not all
data support this. Obesity also decreases SHBG levels, which are
inversely associated with prostate cancer risk. Finally, evidence
indicates that obese men have larger prostates, which may impair
the ability of biopsy to detect tumours, as biopsies sample a
smaller fraction of the total prostate.

Oesophageal cancer
The IARC found sufficient evidence and WCRF/AICR found
convincing evidence that body fatness increases the risk of
oesophageal cancer. Specifically, obesity increases the risk of
oesophageal adenocarcinoma (but not squamous cell carcinoma).
Evidence for weight loss reducing risk of oesophageal reflux and
hence the risk of adenocarcinoma of the oesophagus is growing
(Jacobson et al, 2006). Merry et al examined the change in BMI
and found that a gain of 1 kg m 2 after the age of 20 years
increased the risk of oesophageal adenocarcinoma by 14%; those
with a gain greater than or equal to 8 kg m 1 had 3.4 times the risk
as those with an increase between 0 and 3.9 kg m 2 (Merry et al,
2007). A significant increase in risk of gastric cardia adenocarcinoma was also found. Subsequent reports have also found
increased risk for abdominal fatness, body fatness and oesophageal
adenocarcinoma (Kubo and Corley, 2006; Corley et al, 2008).
Higher BMI was also associated with gastric cardia adenocarcinomas (Kubo and Corley, 2006), but abdominal fatness was not
(Corley et al, 2008).
& 2008 Cancer Research UK

Pancreatic cancer
Although IARC found insufficient evidence in 2002, by 2007 the
WCRF/AICR had found convincing evidence that body fatness
increased risk of pancreatic cancer and abdominal fatness
probably increased risk. In a meta-analysis of cohort data, the
WCRF/AICR reported a 14% increased the risk of pancreatic
cancer for every 5 kg m 2 increase in BMI. Subsequent reports
have been conflicting (Lo et al, 2007; Stolzenberg-Solomon et al,
2008).

Endometrial cancer
In 2002, IARC found sufficient evidence that obesity increased the
risk of endometrial cancer. The WCRF/AICR meta-analysis found
a 52% increase in risk for every 5 kg m 2 increase in BMI and a
31% increase in risk for every 5 kg m 2 as a young adult. Although
this does not provide direct evidence that weight gain increases the
risk of endometrial cancer, it does suggest that changes in BMI
from young adulthood are important. The WCRF/AICR also found
probable evidence that abdominal fatness increases the risk of
endometrial cancer.

Kidney and renal cell cancer
Nearly all studies included in the WCRF/AICR report found an
increased risk of kidney cancer with increased BMI. A metaanalysis found a 31% increase in risk for each 5 kg m 2 increase in
BMI based on cohort data and a 205% increase in risk based on
case – control data. More recent reports have supported the WCRF/
AICR findings and have suggested that weight cycling may
increase the risk of renal cell cancer (Luo et al, 2007; Setiawan
et al, 2007).

SUMMARY OF EVIDENCE
Studies now support weight loss after menopause as a means to
reduce risk of breast cancer. Weight loss is associated with lower
risk of gastroesophageal reflux, a plausible component of the
pathway from adult obesity to adenocarcinoma of the oesophagus.
Limited evidence also suggests that weight loss may reduce the risk
of prostate cancer. For other cancer sites, there is limited evidence
that weight gain and BMI are related to cancers. Obviously, to
increase adult BMI, one must gain weight, and accordingly the
IARC concluded its recommendation to avoid adult weight gain.
Thus, at a minimum, recommendations should emphasise weight
maintenance. Given the substantial body of evidence from
randomised controlled trials that weight loss reduces the risk of
diabetes (Diabetes Prevention Program Research Group, 2002) and
improves blood pressure and blood lipids (NHLBI Obesity
Education Initiative Expert panel on the Identification, 1998),
weight loss can be recommended to produce health benefits for
overweight and obese adults. We outline strategies for weight loss
in an accompanying Supplementary Information.

WHY A PREVENTION TRIAL WITH CANCER AS AN
END POINT IS NOT FEASIBLE
The challenges of sustaining preventive interventions over the long
time periods necessary for primary prevention of cancer have been
thoroughly described by Zelen (1988). Importantly, he emphasised
that over time non-compliance would reduce the power of a study
as the intervention and control arms become more similar. This
was observed empirically in the Women’s Health Initiative
randomised controlled trial where over 42% of women assigned
to combination oestrogen plus progestin had ceased taking their
medication during an average of 5.2 years on study and some
British Journal of Cancer (2008) 99(7), 995 – 999
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10.7% of women assigned to placebo had begun taking postmenopausal hormone therapy (Rossouw et al, 2002). In the study’s
diet intervention, adherence was low (31.4% at year 1) and fell to
14.4% at year 6 (Beresford et al, 2006). The Women’s Health
Initiative Dietary Modification Trial assigned women to a
dietary modification that resulted in a weight loss among the
intervention group, whereas the control group gained weight
between baseline and year 3 (Beresford et al, 2006). The trial found
a nonsignificant reduction in the risk of colorectal or breast
cancers (Prentice et al, 2007). There was a suggestion of decreased
risk of ovarian cancer (Prentice et al, 2007). However, it is unclear
whether the risk reduction was due to the low fat diet or the
concurrent weight loss.
A common approach in cancer prevention trials has been to
identify participants at high risk of cancer. For weight loss and
cancer prevention, this translates to recruiting overweight and
obese participants, a strategy that can very likely lead to
substantial ethical concerns regarding stopping rules based on
prevention of diabetes and other short-term health benefits likely
to be observed long before cancer risk reduction is detected.
In addition, for colon cancer, screening strategies in usual care
are likely to eliminate detectable benefits or reduce the incidence
of disease and thereby lead to large sample size necessary to
detect differences in outcomes in a prevention trial. Likewise for
breast cancer, the growing use of Selective Oestrogen Receptor

Modulators among high-risk women will most likely reduce the
effect of weight loss and associated reductions in hormone levels.
On the basis of these concerns, it is unlikely that in the near
future a cancer prevention trial will focus on weight loss as a
primary prevention strategy, despite the evidence for benefit
through weight control and weight loss that we have reviewed.

CONCLUSION
If individuals achieve and maintain weight loss, we could prevent
substantial cancer burden. This is most evident for postmenopausal breast cancer. The time frame for the benefits of reduced
cancer incidence after successful weight loss remains unclear for
most cancers.
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